Bristol-myers Squibb Compnay

Roche Innovation Center Copenhagen A/s

Jere E Meredith, Jr

Nino Devidze

Richard Eric Olson

Annapurna Pendri

Peter Hagedorn

Marianne Lerbech Jensen

Angela Marie Cacace

James K Loy

Carl J Baldick

Rex Denton

Edward L Halk

Ivar M McDonald

Ivar M Mcdonald

Michael K Ahlijanian

John David Graef

The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

Antisense oligonucleotides targeting alpha-synuclein and uses thereof

Disclosed herein are anti-&#x3b1;-synuclein antibodies which preferentially bind to oligomeric &#x3b1;-synuclein over monomeric &#x3b1;-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.

Antibodies to alpha-synuclein and uses thereof

The present invention relates to the biomarker TFF-3 that measures &#x3b3;-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by &#x3b3;-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.

Method of generating a dosing schedule using gamma secretase notch biomarkers

Gamma secretase notch biomarkers

Growing community of inventors

Haddam, CT, United States of America

Jere E Meredith, Jr